Eupraxia Pharmac SEC Filings

Amendment No. 1 to a Schedule 13D reports that Joseph S. Freedman increased his beneficial stake in Eupraxia Pharmaceuticals Inc. (EPRX) by purchasing 543,130 common shares in an underwritten public offering at $5.50 per share, for an aggregate purchase price of $2,987,215 paid from his personal funds. The filing shows the Reporting Person now beneficially owns 5,533,215 shares (including common shares, preferred-share equivalents, options and warrants), representing 10.2% of the issuer's diluted common-equivalent share count based on the issuer’s reported outstanding shares.

The amendment discloses a customary 90-day lock-up agreement with the offering underwriters restricting transfers, and option agreements granting certain consultants the ability to purchase 60,000 common shares from shares beneficially owned by the Reporting Person. No other transactions in the prior 60 days were reported.

Eupraxia Pharmaceuticals is offering common shares and other securities under a shelf prospectus for aggregate proceeds up to US$200.0 million. The supplement describes an at-the-market/underwritten offering with per-share pricing shown at US$5.50 and related totals (e.g., US$70,000,001.50 and US$65,100,001.39 depending on options). Proceeds are allocated to clinical development, scale-up and corporate purposes, with explicit estimated line items including US$28.4 million, US$5.0 million, US$7.1 million and US$3.4 million. The company is developing EP-104 family products: EP-104IAR (knee OA) and EP-104GI (EoE), with ongoing Phase 1b/2a and Phase 2/Phase 3 planning and FDA interactions described. The prospectus details securities, dilution mechanics, tax and PFIC considerations for U.S. holders, risks including regulatory, clinical trial, funding and commercialization uncertainties, and potential reliance on partners and CROs.

Eupraxia Pharmaceuticals Inc. is offering securities under a shelf prospectus of up to US$200,000,000 in one or more series, including common shares, preferred shares, debt, warrants, subscription receipts and units. The prospectus supplement discusses two lead product candidates: EP-104IAR (intra-articular injections for knee osteoarthritis; completed a Phase 2 study) and EP-104GI (submucosal injections for eosinophilic esophagitis; open-label Phase 1b/2a RESOLVE trial ongoing). The company received pre-IND/FDA feedback and reached agreement with FDA on late-phase requirements for EP-104IAR and program requirements for EP-104GI. The filing notes material risks: significant additional funding will be required, development and regulatory approval are uncertain, clinical CRO performance and manufacturing/GMP compliance are necessary, potential dilution from existing warrants/options/convertible securities (including 8,905,638 Series 1 Preferred Shares at C$5.00) and loss of foreign private issuer status could increase U.S. compliance costs. The company may seek partners for development and plans to allocate proceeds to clinical development, R&D, manufacturing scale-up and general corporate purposes.

EUPRAXIA PHARMACEUTICALS INC. submitted a Form 6-K reporting its principal executive office address in Victoria, British Columbia, and indicated it files annual reports under Form 40-F. The report includes an exhibit: Exhibit 99.1, a press release dated September 22, 2025. The document is signed by Alex Rothwell, Chief Financial Officer, dated September 22, 2025. The filing appears to be a routine disclosure providing company contact details, the chosen annual-reporting form and a referenced press release.